Intensity Therapeutics (INTS) stock underwent a massive rally on Thursday after the clinical-stage biotechnology company announced results from its Phase 1/2 IT-01 study. This study tested the use of INT230-6 as a treatment for heavily pretreated patients with advanced disease having over 20 different types of cancer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The big news from this clinical trial was that INT230-6 achieved a disease control rate of 75% and a median overall survival of 11.9 months. Additionally, the drug treated more than 40% of patients’ total tumor burden. Adding to that, 20% of patients in the less-than-40% group saw their tumors shrink. There were also no dose-limiting toxicities among 64 monotherapy patients, and only seven patients experienced a grade 3 adverse event.
Intensity Therapeutics founder, President, and CEO Lewis Bender stated, “Given the drug’s mechanism of action and the data reported in this paper from over 20 types of metastatic solid cancers, such as breast, sarcoma, pancreatic, lung, and head and neck, we believe the study results show the potential of INT230-6 to achieve clinical benefit for metastatic patients of multiple cancer types with or without the use of radiation, systemic drugs or immunotherapy. As a result, we have initiated randomized controlled studies, including a Phase 3 study in sarcoma.”
Intensity Therapeutics Stock Movement Today
Intensity Therapeutics stock was up 193.74% in pre-market trading on Thursday, following a 5.95% rally yesterday. The shares were down 84.84% year-to-date and 91.79% over the past 12 months.
Today’s clinical trial news spurred heavy trading of INTS stock. With that came some 279 million shares traded, compared to a three-month daily average of about 5.11 million units.
Is Intensity Therapeutics Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Intensity Therapeutics is Moderate Buy, based on two Buy ratings over the past three months. With that comes an average INTS stock price target of $2.25, representing a potential 743.01% upside for the shares.
